Congo's Ebola outbreak reaches 260 cases as testing races to contain spread

The count keeps climbing. As of Saturday, the Democratic Republic of Congo had confirmed 260 cases of Ebola, a figure that Health Minister Roger Kamba announced at a press conference in Bunia, the city where the outbreak took root. The number itself was an update—officials had revised their estimates upward as they worked to understand the true dimensions of what they were facing. The virus spreading through the country belongs to a rare strain called Bundibugyo, one that had not dominated headlines in recent years, which meant much about its behavior remained uncertain.

The geographic reach was already substantial. Cases had been reported across more than a dozen health zones spanning three separate provinces, a pattern that suggested the virus was moving through communities faster than containment efforts could keep pace. Uganda, Congo's neighbor to the east, had recorded nine cases of its own, and one person there had died. The border between the two countries, porous and traveled, had become a vector for transmission.

What made the situation particularly precarious was the gap between what officials knew and what was actually happening on the ground. Doctors Without Borders, the medical organization working in the affected areas, issued a warning that the epidemic was likely spreading faster than response teams could fully track. Hundreds of samples from suspected cases were still waiting to be tested, sitting in backlogs that meant days or weeks might pass before a diagnosis was confirmed. By then, an infected person could have exposed dozens of others. The organization's assessment was not alarmist—it was a straightforward acknowledgment of the limits of the response infrastructure.

There was, however, a potential tool on the horizon. The U.S. health authorities had agreed to support Congo's efforts to test an experimental antibody treatment in a mid-stage clinical trial. Kamba described the medication as "very promising," language that suggested real hope but also the reality that nothing was yet proven. The trial would help determine whether the treatment actually worked, whether it could reduce mortality or speed recovery. In an outbreak where the confirmed death toll was already climbing and hundreds more remained untested, the promise of a new therapeutic option carried weight.

The challenge ahead was twofold: first, to test the people who were sick or suspected of being sick, to know the true scale of the outbreak and where it was moving next; second, to deploy whatever tools existed—whether established protocols or experimental treatments—quickly enough to matter. The Bundibugyo strain was rare enough that the global medical community was still learning how it behaved in this particular context, in these particular communities. The next weeks would determine whether the response could outpace the spread.